Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-onset systemic sclerosis
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hideaki Tsuji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Autoantibodies. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile- and adult-onset systemic sclerosis (SSc).
Methods
Autoantibodies and survival rates over a maximum of 20 years were retrospectively analysed in 504 Japanese patients with SSc (juvenile-onset SSc, n = 17; adult-onset SSc, n = 487) using data from Kyoto University Registry.
Results
The autoantibodies observed were anti-topoisomerase-I (71% vs. 26%), anti-centromere (24% vs. 54%), and anti-RNA-polymerase-III (0% vs. 12%). A diffuse type and multiorgan involvement were observed in patients with anti-topoisomerase-I in both juvenile- and adult-onset SSc. In patients with anti-centromere, a diffuse type (juvenile-onset SSc vs. adult-onset SSc, 75% vs. 28%) and pulmonary fibrosis (50% vs. 17%) were more frequently observed in juvenile-onset SSc than in adult-onset SSc. Cox proportional hazard analyses showed that older onset (hazard ratio: 1.06, 95% confidence interval: 1.03–1.09) was associated with death, while autoantibodies were not significantly associated with death. Cumulative survival rates for 20 years were similar between juvenile- and adult-onset SSc when classified based on the presence of anti-centromere (100% vs. 89%, P = .20) and anti-topoisomerase-I (90% vs. 90%, P = .70).
Conclusions
Juvenile-onset SSc had more frequent diffuse-type and anti-topoisomerase-I. An older onset was slightly associated with mortality, whereas autoantibodies were not associated with mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ORCID-Profile: Hideaki Tsuji, Mirei Shirakashi, Ryosuke Hiwa, Hajime Yoshifuji
Zitieren
APA
Tsuji, H., Shirakashi, M., Hiwa, R., Akizuki, S., Nakashima, R., Onishi, A., Yoshifuji, H., Tanaka, M., & Morinobu, A. (2025). Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-onset systemic sclerosis. Modern Rheumatology. https://doi.org/10.1093/mr/roaf005
Vancouver
Tsuji H, Shirakashi M, Hiwa R, Akizuki S, Nakashima R, Onishi A, et al. Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-onset systemic sclerosis. Modern Rheumatology. 2025. doi:10.1093/mr/roaf005
BibTeX
@article{Tsuji2025,
author = {Tsuji, Hideaki and Shirakashi, Mirei and Hiwa, Ryosuke and Akizuki, Shuji and Nakashima, Ran and Onishi, Akira and Yoshifuji, Hajime and Tanaka, Masao and Morinobu, Akio},
title = {Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-onset systemic sclerosis},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf005}
}
EUVIMED